SecBot SecBot
SECBOTREPLAY Home › Report › ABUS

ABUS · Arbutus reported Q1 2026 GAAP EPS of $0.87 (diluted), a massive beat vs

Arbutus Biopharma Corporation · PRESS-RELEASE filed May 13, 2026 at 07:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed May 13, 2026 at 07:30 ET

Arbutus reported Q1 2026 GAAP EPS of $0.87 (diluted), a massive beat vs. consensus of -$0.06, driven by $178.7M in license revenue from the Moderna settlement. Revenue surged to $179.1M from $1.8M YoY, and the company ended the quarter with $95.2M in cash. The stock will move on the magnitude of the settlement cash inflow and the FDA Fast Track designation for imdusiran, though the core business remains pre-revenue.

  • Q1 2026 GAAP diluted EPS $0.87 vs consensus -$0.06 (beat by $0.93)
  • Total revenue $179.1M vs $1.8M YoY, driven by $178.7M license revenue from Genevant/Moderna settlement
  • Net income $169.7M vs net loss $24.5M YoY
  • Cash, cash equivalents and marketable securities $95.2M as of March 31, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access